Cyprium Therapeutics, a subsidiary of Fortress Biotech, has had its New Drug Application for CUTX-101 accepted for priority review by the FDA, with a decision expected by June 30, 2025; Cyprium will receive royalties and up to $129 million in milesto
AI Assistant
FORTRESS BIOTECH INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.